Understanding DATAR EXACTA™ Testing
A plain-language guide to advanced molecular tumor profiling — what it is, what it offers, and how to think through the decision.
If you are reading this, you are probably holding a great deal right now.
You may be sorting through medical information that feels dense and technical. You may be weighing a significant financial decision on top of an already difficult situation. You may be trying to think clearly when thinking clearly feels harder than it ever has.
This guide was written with all of that in mind.
What you will find here is straightforward: a clear, honest explanation of what DATAR EXACTA™ testing is, what kind of information it can and cannot provide, and how to think through whether it makes sense for your situation.
This is not a document designed to lead you to a particular decision. There is no right answer waiting at the end of it. Advanced molecular testing is one option available to some individuals navigating complex or difficult-to-treat cancers. It is not the only option. It is not the right option for everyone.
Read it in sections if that feels better. Come back to parts of it. Where there is uncertainty, we say so. Where limitations exist, we name them. A complete picture — including its difficult edges — is more useful than a curated one.
Take your time with this.
A complete picture — including its difficult edges — is more useful than a curated one.
Adele Kulyk · Founder, Calm Over Cancer
Before You Begin
What this guide is, why it was written, and how to begin.
Why Precision Testing Exists
Cancer is not one disease.
When a cancer is diagnosed, it is typically named by where it originates. Standard treatment protocols are built around these categories — developed through decades of research, large clinical trials, and carefully observed outcomes. That work is real, rigorous, and important.
And yet.
Two individuals can receive the same diagnosis and respond to the same treatment in completely different ways. The reason lies beneath the surface, at the molecular level. Every cancer has a biological architecture that is unique to the individual in whom it develops — which genes are active, which pathways the cancer is using to grow, survive, and resist treatment.
This is the gap that precision testing was developed to address. Rather than relying solely on what is known about a cancer type in general, molecular profiling looks at what is actually happening in a particular cancer — at the level of its genes, its active pathways, and its biological behavior. This does not mean standard care is insufficient. What precision testing offers is additional resolution — a clearer biological picture.
Consider a weather forecast.
A forecast tells you what conditions are likely across a wide region. Standard oncology protocols are like a regional forecast: carefully built from the best available data, and an essential starting point.
Molecular profiling is like placing a precise instrument at your specific location — to measure what is actually occurring there. Neither replaces the other. Together, they offer a clearer picture.
Precision testing does not replace what is known about cancer in general. It adds resolution to what is happening in one specific case.
What EXACTA™ Is
DATAR EXACTA™ is an advanced molecular analysis developed by Datar Cancer Genetics — an organization specializing in precision oncology, established in 2013, with more than a decade of specialized experience in tumor biology and genomic research.
It is not a single test.
EXACTA™ is a coordinated analysis that examines multiple layers of biological information simultaneously — gathering different types of data from blood, tissue, or both — and integrates all of that into a unified picture of how a particular cancer is behaving. The goal is not simply to identify what is present in a cancer. The goal is to understand what is driving it.
The output is a personalized therapy recommendation — a document that synthesizes the findings across every layer of testing and translates them into a ranked, clinically informed set of treatment options, drawn exclusively from FDA-approved medications.
Think of it like a full structural assessment of a building.
A standard inspection identifies the most visible issues. But if a building has a complex, persistent problem, a more thorough assessment becomes valuable — one that looks at the foundation, the load-bearing structure, the electrical systems, all at once, in relationship to each other.
EXACTA™ approaches tumor biology with that same logic — examining the underlying structure so that treatment decisions can be made with a fuller understanding of what they are addressing.
Each layer of analysis tells a different part of the story. Together, they offer a level of biological detail that a single test cannot provide alone.
Understanding EXACTA™
What the testing is, what it looks at, and what it may offer.
What EXACTA™ Actually Looks At
EXACTA™ reads six distinct layers of biological information simultaneously. Each captures something the others cannot.
The Genetic Blueprint
What structural changes are present in the cancer's genetic code.
Identifies mutations across hundreds of cancer-relevant genes. Tissue: 511 genes. Blood ctDNA: 409 genes.¹
What's Actually Switched On
Which genes are actively influencing the cancer's behavior right now.
Measures gene activity across 20,805 genes — which ones are actively contributing to the cancer's behavior at time of testing.¹
How the Cancer Responds to Treatment Directly
Testing how living cancer cells respond when exposed to specific drugs.
Unique to blood-based testing. Tumor-associated cells exposed to FDA-approved medications — the closest approximation to observing drug response before treatment begins.¹
The Immune Environment
Whether the immune system may play a meaningful role in treatment.
Examines markers indicating whether immunotherapy is worth considering — or less likely to be useful — for this individual's cancer.¹
How the Body Processes Medication
How an individual's own biology affects the way specific drugs are used.
Examines genetic variations influencing how the body metabolizes medications — ensuring recommendations account for the individual's biology as well as the cancer's.¹
The Roads the Cancer Is Using
Which biological systems the cancer appears to rely on to grow and survive.
Maps active biological pathways using one of the most comprehensive gene and pathway databases in oncology research — identifying potential points of intervention.¹
Panel specifications confirmed from peer-reviewed clinical research.¹
No single layer tells the whole story. The value of this analysis lies in what becomes visible when all of them are considered together.
Tissue Testing vs. Blood Testing
There are two sample options: tissue and blood. Each provides different biological information. This is not a question of one being superior — it is a question of what each can show, and what the clinical situation makes available.
Tissue Testing
Tissue samples come from a biopsy or from tissue that was surgically removed. Tissue-based testing allows for deep molecular analysis of the tumor's DNA, gene activity, and active pathways. The important limitation is one of timing: tissue reflects the biology of the cancer at the time it was collected. Tissue testing also does not allow for live drug sensitivity testing — preserved cells are no longer active.
Blood Testing
A fresh blood draw collects tumor-associated cells and cell-free DNA shed by the tumor. Because these cells are living at collection, they can be used for direct, live drug sensitivity testing — information about how the cancer is behaving right now. The limitation: tumor-associated cells may not always be present in sufficient numbers.
Tissue Testing
Sample type
Biopsy or surgical tissue — fresh or preserved
Live drug sensitivity
No — preserved cells are not active
Timing
Reflects biology at time of collection
New procedure?
Not always — existing tissue can be used
Blood Testing
Sample type
Fresh blood draw
Live drug sensitivity
Yes — living cells observed directly
Timing
Reflects current tumor activity
New procedure?
Yes — fresh blood draw required
When Both Are Used Together
Tissue explains the underlying molecular architecture. Blood reflects what is happening right now. Together, they offer the most complete picture available.
Results are typically returned within 21–28 days of the laboratory receiving the sample.²
Tissue shows where the cancer has been, biologically. Blood reflects where it is now. Together, they reduce the gaps in the picture.
What the Results Include
When EXACTA™ testing is complete, the findings are compiled into a structured report — a detailed clinical resource intended to support more informed treatment conversations. The report is not a diagnosis. It is a tool with six distinct components, each addressing a different clinical question.
Component 1
Therapy Recommendations
Which FDA-approved treatments appear most relevant to this tumor's biology?
Component 2
Ranked Treatment Options
In what order should these options be considered, based on molecular evidence?
Component 3
Molecular Findings
What specific genetic and biological alterations were identified?
Component 4
Pathway Analysis
Which biological systems does the cancer appear to be relying on?
Component 5
Pharmacogenetic Guidance
How may this individual's biology affect how specific drugs are processed?
Component 6
Clinical Trial Matching
Which trials may be relevant based on the molecular profile?
The report expands what is known. The clinical team determines what is done with that knowledge. Both roles matter — and neither replaces the other.
Who This Is Designed For
Honest guidance on where deeper testing tends to add value — and where it may not.
Where EXACTA™ Tends to Be Most Relevant
Advanced molecular testing is not the right next step for every person navigating cancer. This section is designed to help you think more clearly about whether deeper biological analysis is worth a serious conversation in your specific situation.
When standard treatment has not produced the expected response
Deeper molecular analysis can sometimes identify biological characteristics that help explain an unexpected response, and point toward options that standard protocols may not have surfaced.
When cancer has recurred after previous treatment
A cancer that returns has demonstrated some capacity to persist through what was offered. Understanding the current molecular behavior — not just the original profile — can be genuinely useful.
When treatment options feel limited or unclear
A more comprehensive biological picture may reveal avenues not visible through standard testing — including off-label uses of approved medications or clinical trials matched to specific molecular findings.
When a newly diagnosed cancer is known to be complex or difficult to treat
Some individuals and care teams choose to pursue deeper molecular analysis early, before committing fully to a treatment path. This benefits from oncologist input and should not be made in isolation.
When the risk of treatment failure feels high
Having additional biological data before committing to a significant course of treatment is a legitimate reason to consider deeper testing.
Questions worth sitting with
The following are not criteria or checklists. They are questions worth sitting with — and worth bringing to a clinical conversation. None has a single correct answer.
Has the current treatment approach produced the response that was expected?
Has the cancer returned after a period of response or stability?
Are available treatment options limited, unclear, or feeling increasingly narrow?
Is there a sense that important biological information may be missing from the current clinical picture?
Is the care team open to incorporating molecular findings into treatment planning conversations?
Is there enough clinical stability to allow time for testing and result interpretation before the next treatment decision?
The question is not whether this testing is impressive. The question is whether it is likely to contribute something meaningful to the decisions being made — in this situation, at this moment.
Where EXACTA™ May Not Be the Right Fit
Is this testing actually necessary for me?
The answer, in many situations, is: it may not be.
Advanced molecular testing represents one tool in a much broader landscape of oncology care. There are contexts where the current clinical pathway is already well-informed, well-matched, and well-supported — and where additional testing would add complexity without adding proportionate clarity.
When standard oncology pathways may already provide what is needed
For many individuals with early-stage cancers and well-established treatment protocols, standard oncology care already offers a thoughtful, evidence-based path forward. When a cancer is detected early and the care team has a confident plan, comprehensive testing may not meaningfully change what is recommended.
When treatment is already underway and producing a response
Molecular profiling is most useful when there is a genuine clinical question that current information cannot answer. When treatment is working and the path forward is clear, that question may not exist yet.
When overall clinical condition limits practical options
Information is only as useful as the capacity to act on it. Pursuing testing is not always an act of care. Sometimes it is an act of avoidance — a way of feeling as though something is being done when the more important conversation is a different one entirely.
When timing does not allow for meaningful integration
When clinical urgency requires that treatment begin immediately, the practical value of comprehensive testing diminishes significantly.
That feeling is understandable. It comes from care.
But information-gathering has a practical limit. Sometimes EXACTA™ testing contributes meaningfully. Sometimes the right information is already in the room.
More information is not always better information. Sometimes the most useful thing a thorough process can confirm is that the path already being taken is the right one.
What the Evidence Shows
What published research demonstrates — and what it honestly cannot promise.
Real-World Evidence
Does this actually help?
The short answer is: for some individuals, in some situations, precision-informed treatment approaches have produced meaningful clinical benefit. The evidence is real and growing. It is also incomplete, still evolving, and more complex to interpret than a simple success rate would suggest.
Precision oncology is difficult to study using traditional trial models because every recommendation is tailored to a specific molecular profile. This does not mean the evidence is absent or unimportant. It means it is generated and interpreted differently — and needs to be understood on its own terms.
Published Findings
A peer-reviewed real-world study examined outcomes in 44 individuals with metastatic solid tumors who had exhausted guideline-based treatment options — conducted at a specialist oncology practice in Germany and published in the Journal of Oncology Research and Therapy in June 2025.³
These findings come from one peer-reviewed real-world retrospective cohort study. The study's authors note that prospective validation in larger cohorts is warranted.³
In this retrospective real-world cohort, individuals receiving molecularly guided therapy experienced a statistically significant improvement in progression-free intervals compared with their prior line of therapy — a median of 30 weeks following molecular guidance, compared to 22.5 weeks on their preceding treatment (p = 0.003). Seventy percent of individuals showed measurable benefit with stable functional status.³
Among a smaller group of individuals who received targeted biological therapy — ten individuals in total — median progression-free survival reached 61 weeks. This subgroup was small, and the difference between therapy types did not reach conventional statistical significance. It is offered here as a directional signal, not a definitive finding.³
Recommendations that incorporated gene expression analysis appeared to be associated with somewhat longer progression-free intervals compared to those based on DNA analysis alone. This trend was observed but did not reach statistical significance in this study.³
The study's authors describe their findings as directional — noting that prospective validation in larger cohorts is warranted. That characterization reflects the honest state of the field.³
Precision oncology offers a more detailed biological picture and a more informed starting point. What it cannot offer is certainty. In medicine, that distinction always matters.
Honest Limitations
Every tool in medicine has boundaries. Understanding those boundaries clearly, before making a decision, is part of making a genuinely informed choice.
Not all findings become actionable
Not all molecular findings point clearly toward a therapeutic option. Results exist on a spectrum — from highly actionable to informative but not immediately useful.
Some recommended therapies may not be accessible
Some recommendations involve off-label use of FDA-approved medications. Insurance coverage for off-label therapies varies significantly and is not guaranteed.
Biology remains unpredictable
Molecular matching improves the biological rationale for a treatment decision. It does not override the fundamental complexity of individual biological response. Molecular profiling reduces uncertainty. It does not eliminate it.
Cancers continue to evolve
A molecular analysis reflects the biology of a cancer at a specific point in time. Cancers change in response to treatment, time, and their own internal biological pressures. Any single result is a snapshot rather than a permanent biological truth.
Treatment decisions still require clinical judgment
The EXACTA™ report does not make clinical decisions. Every recommendation must be evaluated by a clinician in the context of the individual's full medical picture.
The report informs. The conversation decides.
The Emotional Limitations
More information does not always produce more certainty. Some people find that having more detailed information does not reduce the difficulty of the decisions ahead. The decisions become more informed. They do not become easier.
Data and peace of mind are related, but they are not the same thing.
Some questions that feel most urgent — will this work? what should I do? — are not questions that any test can answer. The researchers behind the real-world study referenced in this guide describe their findings as directional signals — noting that prospective validation in larger cohorts is warranted.
Uncertainty is not a sign that something has gone wrong. It is part of medicine itself — and naming it honestly is more useful than pretending it away.
Making a Decision
Thinking clearly about a meaningful choice — without pressure, without guilt.
Understanding the Investment
Advanced molecular testing represents a significant financial commitment. That reality deserves to be named directly — not minimized, not justified, and not dressed up in language that makes it easier to overlook.
This section is not going to tell you that it is worth it. That determination belongs to you, made carefully, in the context of your situation, your finances, and what you are actually hoping the testing will help you understand.
What the cost reflects
EXACTA™ is not a single laboratory test. It is a multi-layered molecular analysis integrating genetic sequencing, gene activity measurement, live drug sensitivity testing, immune marker analysis, pharmacogenetic profiling, and pathway analysis into a unified, personalized report. Results are typically returned within 21–28 days of the laboratory receiving the sample.²
More expensive does not mean more appropriate
The value of any diagnostic tool depends entirely on whether the information it generates can be meaningfully integrated into the decisions being made. The question is never simply: is this good testing? The question is: is this testing likely to add something meaningful to this situation, at this moment?
The emotional pressure to pursue every option
There is a particular kind of pressure that settles on people navigating serious illness — a feeling that every possible avenue must be explored. That feeling is understandable. It comes from love, from fear, from the very human desire to feel that everything possible is being done. But decisions made primarily from that pressure are not always the most useful ones.
Before deciding, consider
Is the care team open to incorporating molecular findings into treatment discussions?
Is there enough clinical stability to receive results and act on them thoughtfully?
Is there access to appropriate interpretive support?
A Practical Note on Drug Costs and Insurance
The cost of EXACTA™ testing is separate from the cost of any treatments that may subsequently be recommended. Oncologists can use molecular findings to support insurance coverage requests. Coverage is not guaranteed for off-label uses, but the molecular rationale can strengthen prior authorization requests.
Manufacturer assistance programs and patient foundation grants exist that can significantly reduce costs for specific medications once a treatment path has been identified.
Some individuals will decide that testing feels appropriate and worthwhile. Some will decide the timing is not right. Some will decide the financial tradeoff does not make sense. Some will want to discuss it further with their care team before deciding anything.
All of these are reasonable outcomes.
Decisions made from pressure rarely serve people as well as decisions made from clarity.
The decision that matters most is not whether to pursue testing. It is whether the decision — whichever direction it goes — was made from clear thinking rather than pressure, and from honest reflection rather than fear.
A Framework for Thinking This Through
This section is not going to add more information. It is going to help you slow down and think about what you already have. Good decisions about complex medical questions are rarely made quickly — they are made in conversation, after reflection, not in the middle of it.
The questions that follow are not a checklist. There are no correct answers. They are simply invitations to think — slowly, honestly, without pressure.
What question am I hoping this testing will help answer?
Testing is most useful when it is being asked to answer a specific question — one that the current clinical picture has not adequately addressed. Not every feeling of uncertainty translates into a question that molecular analysis is positioned to answer.
Would the findings meaningfully influence the decisions currently being considered?
Information is most useful when it can be acted upon. If the answer to whether results will influence what happens next is uncertain, that uncertainty is worth exploring before the testing is pursued.
Is there enough time and clinical stability to use the findings thoughtfully?
Results that arrive after a treatment decision has already been made are significantly less useful. This is not a reason to delay indefinitely — it is a reason to consider whether the current moment is the right one.
Am I seeking clarity, certainty, reassurance, or direction?
Testing can contribute to clarity. It can inform direction. It cannot provide certainty. Being honest about what you are hoping to find on the other side of this decision is one of the most useful things you can do before making it.
What would make this testing feel genuinely useful in this situation?
Not generally useful. Not useful in principle. Useful here, now, in this specific context. If you can describe what you would do differently, or what conversation you would be better equipped to have, then you have a clear sense of what you are looking for.
A decision made quickly from pressure is not a stronger decision than one made carefully from reflection. Discuss this with your care team. Discuss it with the people who know you well.
There is no deadline on thinking clearly.
A good decision is not one that moves in a particular direction. It is one that was made carefully, honestly, and with a clear sense of what actually matters in this situation — right now.
Learn More & Next Steps
Continued understanding, available support, and a closing thought.
Hear It From a World Expert
Reading about molecular oncology is one way to build understanding. Hearing it discussed — by someone who has spent decades working at its leading edge — is another. A conversation moves differently. It follows curiosity. It pauses on the parts that need more room.
Dr. Chirantan Bose
Molecular Pathologist & Precision Oncology Specialist
Head, Department of Molecular and Precision Oncology
M | O | C Cancer Care & Research Centre, Mumbai
In this episode, Dr. Bose discusses the reasoning behind advanced molecular tumor analysis — why it was developed, what it is designed to do, where it adds meaningful clinical value. He is thoughtful. He is measured. He does not overstate what the science can offer. This is not a promotional interview. It is a genuine scientific conversation.
Listen on Spotify
Episode 14 — Dr. Chirantan BoseLiving With Cancer Podcast · No medical background required · Approx. 40 minutes
This episode was recorded during Dr. Bose's tenure at Datar Cancer Genetics. He has since moved into his current role at M | O | C Cancer Care & Research Centre. The science he discusses remains directly relevant and current.
Understanding builds gradually — through reading, through listening, through conversation, and through the questions that surface when complex ideas begin to feel more familiar.
How Calm Over Cancer Supports You
Who actually helps people make sense of all this?
Receiving complex molecular information and knowing how to use it are two different things.
A comprehensive molecular report contains significant biological detail. It is also, for most people without a background in genomics or molecular pathology, genuinely difficult to navigate without support. This is not a reflection of anyone's intelligence. It is a reflection of the nature of the information itself.
What Calm Over Cancer Actually Does
Organizing what the report actually contains
Part of the support COC offers is helping individuals understand the structure of what they have received, so that the volume of information feels manageable rather than overwhelming.
Identifying what may be most relevant
Not every finding carries equal clinical weight. Helping individuals understand that distinction — so they are not treating every line of the report as equally urgent — is one of the most practically useful things support can provide.
Translating findings into language that supports clinical conversations
Part of COC's role is helping individuals organize their questions, articulate what they have learned, and enter clinical conversations better prepared to engage with the information shaping their treatment decisions.
Reducing the experience of overwhelm through structured understanding
Structured support — working through complex information systematically, in conversation — restores the capacity to think clearly. And clear thinking is what good decisions are built from.
What Calm Over Cancer Does Not Do
COC does not replace oncology care. The relationship with a treating oncologist remains the clinical center of cancer care.
COC does not make treatment decisions. Every treatment decision belongs with the individual, their family, and their medical team.
COC does not eliminate the uncertainty that serious illness brings. What support can do is ensure that the uncertainty being navigated is genuine — the irreducible complexity of medicine itself — rather than the added uncertainty that comes from trying to make sense of complicated information without adequate help.
Why This Kind of Support Exists
The gap between receiving complex molecular information and being able to use it well is real. It is a structural gap — one that exists because the science of precision oncology has developed faster than the infrastructure for translating it into everyday clinical conversations.
COC exists in that gap.
Some people arrive having just received a report they cannot begin to parse. Some arrive after months of accumulating questions that have not had anywhere to land. Some arrive before testing, trying to decide whether to pursue it at all.
All of those are reasonable places to start.
The goal is not to replace the clinical expertise that belongs with oncology. It is to make sure that the people who need to use that expertise are genuinely equipped to do so.
You have just moved through a significant amount of complex information.
Not because complexity is the point — but because you deserve an honest picture of what advanced molecular testing is, what it can offer, where it may help, where it may not, and what it genuinely cannot promise.
Even if parts of it remain unclear. Even if you finish this guide with more questions than you started with.
Careful, honest thinking — made as clearly as possible, under genuinely difficult circumstances — is what good decision-making looks like. Not certainty. Not perfect information. Just the best that thoughtful people can do. That has always been enough.
Questions are allowed. Changing your mind is allowed. Needing help making sense of complex information is not a sign that something has gone wrong. It is a reasonable response to information that most people were never trained to interpret.
Sources & References
This guide draws on peer-reviewed clinical research, verified technical specifications, and established oncology literature. Sources are listed below for readers who wish to explore further.
Clinical Research
Schaffrin-Nabe D, Josten-Nabe A, Schuster S, Heinze A, Uhl W, Schaffrin M, Voigtmann R. Real-World Applications of Comprehensive Tumor Profiling for Personalized Cancer Therapy in Metastatic Patients. Journal of Oncology Research and Therapy. 2025;10(2):10289. Published June 9, 2025.
DOI: 10.29011/2574-710X.10289 Source for panel specifications (511 tissue genes, 409 ctDNA genes, 20,805 RNA genes), real-world outcome data, and KEGG pathway confirmation cited in Sections 4 and 9.Technical Specifications
Datar Cancer Genetics. EXACTA™ Comprehensive Tumor Profiling — Technical Specifications and Laboratory Process. Established 2013.
https://datarpgx.com Source for turnaround time (21–28 days, unified range). Confirm current version with Datar Cancer Genetics before final publication.Expert Interview
Bose C. Interview: Advanced Tumor Profiling and Precision Oncology. Living With Cancer Podcast, Episode 14. Dr. Bose currently serves as Head, Department of Molecular and Precision Oncology, M | O | C Cancer Care & Research Centre, Mumbai.
Listen on SpotifyAbout the Testing
Datar Cancer Genetics. EXACTA™ — Encyclopedic Tumor Analysis.
https://datarpgx.comFor clinical questions about precision oncology testing, please consult a qualified oncologist or precision medicine specialist. This guide is an educational resource and does not constitute medical advice.